Long-term trial supports CD19-targeted CAR T cells for relapsed/refractory CLL
0 Mga view
• 07/14/23
0
0
I-embed
administrator
Mga subscriber
In this episode, Mark Geyer and colleagues demonstrate that second-generation CD19-targeted CAR T cell therapy following conditioning chemotherapy is tolerated in patients with relapsed/refractory CLL and can result in complete remission in a subset of patients…
Magpakita ng higit pa
Mga Komento sa Facebook
SORT BY-
Mga Nangungunang Komento
-
Pinakabagong komento